Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting

2024-04-25 10:02:00

SAN FRANCISCO and SUZHOU, China, April 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that about 20 accepted abstracts of clinical data from multiple trials in relation to multiple novel mono-/bi-specific antibodies and antibody-drug-conjugates (ADCs) as well as innovative drugs including TYVYT® (sintilimab injection), olverembatinib, taletrectinib (ROS1 TKI) from its oncology pipeline will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 from May 31 to June 4, 2024, in Chicago, IL, U.S..

Dr. Hui Zhou, Senior Vice President of Innovent, stated: "We are very pleased to present a robust set of clinical data for our next-generation innovative bispecific antibodies and ADC molecules for the first time at the 2024 ASCO Annual Meeting. We observed the preliminary efficacy and safety signals for those innovative candidates, underscoring their potential for further development and clinical value. As one of the few biopharmaceutical companies with both the technology platforms and robust pipeline in "IO+ADC" areas, Innovent will continue to make breakthroughs in the field of cancer treatment, and is committed to providing doctors and patients with more innovative, effective and safe treatment options."

Details on the abstracts are listed below:

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that treat some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has 10 products in the market, 3 new drug applications under the NMPA review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare leaders, including Eli Lilly, Roche, Sanofi, Adimab, Incyte and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

PR Newswire News

2024-05-29
18:00:00
DPC Dash - Domino's Pizza China Shines at Domino's Worldwide Rally 2024 with Multiple Accolades
17:59:00
Lingnan University signs agreements with Rizhao City and Shandong Hi-Speed Group there to foster closer partnerships in green, low-carbon, and AI development
17:51:00
Sinopec Releases Reports Offering Outlooks of China's Energy, Hydrogen and Chemical Development
16:40:00
FWD Group announces solid first quarter new business update
16:36:00
Zoomlion Launches 3D Digital Twin Platform Built for Ready-Mix Concrete Industry
15:39:00
At the 2024 Global Sources Hong Kong Shows, PR Newswire Boosts Impact for Exhibitors
10:00:00
US-Based Neurobiotic Leader Bened Life Launches Global Expansion with Neuralli™ MP
09:00:00
KFin Technologies Limited Convenes Capital Market Leaders at the KFintech Partner Conclave 2024
2024-05-28
22:06:00
SocialFi Infrastructure OpenSocial Protocol Raises $5M to Fuel the Growth of SocialFi Super Apps, with $15M Ecosystem Fund Backed by EVG
21:00:00
ICZOOM & WeBank signed the Supply Chain Finance Strategic Cooperation Agreement
21:00:00
Tencent Deploys AI to Help Researchers Decipher Hidden Meanings in Oracle Bone Scripts
20:00:00
Euro Tech Holdings Company Limited Declared A Special Cash Dividend
18:00:00
OneConnect Announces 2024 Annual General Meeting Results
18:00:00
Trip.com Group to Hold Annual General Meeting on June 18, 2024
18:00:00
Baozun Announces First Quarter 2024 Unaudited Financial Results
15:49:00
On-us Selected for the Prestigious Visa Accelerator Program, Revolutionizing Loyalty of the Future
14:47:00
An Interview with Siju Daniel, Chief Commercial Officer of ATFX
12:18:00
XTransfer and TerraPay Partner to Empower Global SMEs with Enhanced Cross-Border Payment Solutions
12:01:00
Tuya Smart Officially Joins the United Nations Global Compact
08:00:00
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
Back to Top